首页> 外文OA文献 >Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells
【2h】

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells

机译:阳离子脂质组成对抗原提呈细胞中siRNA脂质纳米颗粒制剂基因沉默特性的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lipid nanoparticles (LNPs) are currently the most effective in vivo delivery systems for silencing target genes in hepatocytes employing small interfering RNA. Antigen-presenting cells (APCs) are also potential targets for LNP siRNA. We examined the uptake, intracellular trafficking, and gene silencing potency in primary bone marrow macrophages (bmMΦ) and dendritic cells of siRNA formulated in LNPs containing four different ionizable cationic lipids namely DLinDAP, DLinDMA, DLinK-DMA, and DLinKC2-DMA. LNPs containing DLinKC2-DMA were the most potent formulations as determined by their ability to inhibit the production of GAPDH target protein. Also, LNPs containing DLinKC2-DMA were the most potent intracellular delivery agents as indicated by confocal studies of endosomal versus cytoplamic siRNA location using fluorescently labeled siRNA. DLinK-DMA and DLinKC2-DMA formulations exhibited improved gene silencing potencies relative to DLinDMA but were less toxic. In vivo results showed that LNP siRNA systems containing DLinKC2-DMA are effective agents for silencing GAPDH in APCs in the spleen and peritoneal cavity following systemic administration. Gene silencing in APCs was RNAi mediated and the use of larger LNPs resulted in substantially reduced hepatocyte silencing, while similar efficacy was maintained in APCs. These results are discussed with regard to the potential of LNP siRNA formulations to treat immunologically mediated diseases.
机译:脂质纳米颗粒(LNPs)是目前最有效的体内传递系统,用于使用小分子干扰RNA沉默肝细胞中的靶基因。抗原呈递细胞(APC)也是LNP siRNA的潜在靶标。我们检查了在包含四种不同可电离阳离子脂质即DLinDAP,DLinDMA,DLinK-DMA和DLinKC2-DMA的LNP中配制的siRNA的初级骨髓巨噬细胞(bmMΦ)和树突状细胞中的摄取,细胞内运输和基因沉默能力。含有DLinKC2-DMA的LNP是最有效的制剂,这取决于它们抑制GAPDH靶蛋白产生的能力。同样,如使用荧光标记的siRNA进行的内体与细胞质siRNA定位的共聚焦研究表明,包含DLinKC2-DMA的LNP是最有效的细胞内递送剂。 DLinK-DMA和DLinKC2-DMA制剂相对于DLinDMA具有更高的基因沉默能力,但毒性较低。体内结果显示,含有DLinKC2-DMA的LNP siRNA系统是在全身性给药后沉默脾脏和腹膜腔APC中GAPDH的有效药物。 APC中的基因沉默是RNAi介导的,使用较大的LNP会导致肝细胞沉默大大降低,而在APC中则保持相似的功效。讨论了有关LNP siRNA制剂治疗免疫介导疾病的潜力的这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号